Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Income from Continuing Operations (2016 - 2026)

Organogenesis Holdings has reported Income from Continuing Operations over the past 10 years, most recently at 53200000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 593.34% year-over-year to 53200000.0; the TTM value through Dec 2025 reached 46532000.0, up 5304.41%, while the annual FY2025 figure was 46532000.0, 5304.41% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 53200000.0 at Organogenesis Holdings, up from 21567000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 53200000.0 in Q4 2025 and troughed at 18843000.0 in Q1 2025.
  • A 5-year average of 8202650.0 and a median of 6494500.0 in 2023 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: surged 1450.88% in 2024 and later plummeted 797.29% in 2025.
  • Year by year, Income from Continuing Operations stood at 50995000.0 in 2021, then plummeted by 81.44% to 9466000.0 in 2022, then tumbled by 106.0% to 568000.0 in 2023, then surged by 1450.88% to 7673000.0 in 2024, then skyrocketed by 593.34% to 53200000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for ORGO at 53200000.0 in Q4 2025, 21567000.0 in Q3 2025, and 9392000.0 in Q2 2025.